Fidelity Investments
MRKR icon

Fidelity Investments’s Marker Therapeutics MRKR Stock Holding History

Fidelity Investments’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150
Closed -$134 – 5524
2025
Q3 		$134 Buy
+150
New +$185 ﹤0.01% 5183
2025
Q2 		– Sell
-2
Closed -$2 – 5436
2025
Q1 		$2 Sell
2
-10
-83% -$18 ﹤0.01% 5270
2024
Q4 		$37 Hold
12
– – ﹤0.01% 5243
2024
Q3 		$34 Hold
12
– – ﹤0.01% 5249
2024
Q2 		$65 Hold
12
– – ﹤0.01% 5017
2024
Q1 		$52 Hold
12
– – ﹤0.01% 5026
2023
Q4 		$66 Hold
12
– – ﹤0.01% 4983
2023
Q3 		$55 Sell
12
-72
-86% -$402 ﹤0.01% 4917
2023
Q2 		$260 Buy
+84
New +$146 ﹤0.01% 4877
2019
Q4 		– Sell
-125
Closed -$6K – 4092
2019
Q3 		$6K Buy
+125
New +$7.39K ﹤0.01% 3364

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fidelity Investments's MRKR Position: Q4 2025 in Review

Fidelity Investments sold out of Marker Therapeutics (MRKR) in Q4 2025, closing a stake of 150 shares — an estimated $134 sold.

Fidelity Investments first reported a position in MRKR in Q3 2019 and held it in 10 quarters. The position peaked at $6K in Q3 2019. 36 funds tracked by Wall St. Rank hold MRKR as of Q4 2025.

  • Fidelity Investments reported no remaining Marker Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fidelity Investments sold 150 Marker Therapeutics shares in Q4 2025, an estimated $134.
  • Fidelity Investments first reported a position in Marker Therapeutics in Q3 2019 and held it in 10 quarters.
  • Fidelity Investments's Marker Therapeutics position peaked at $6K in Q3 2019.
  • 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2025.

Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.